----

| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|--------------------------------------------------------------------------------------|
| ☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|------------------------------------------------------------------------------------|
| Nevada                                                         |   | 88-0425691                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|                                                           |   |                                 |
|  555 Wireless Boulevard, Hauppauge, NY                    |   | 11788                                |
| (Address of principal executive offices)                       |   | (Zip Code)                           |
| Title of each class           |   | Trading symbol |   | Name of each exchange on which registered |
|-------------------------------|--------|----------------|--------|-------------------------------------------|
| Common Stock, $0.01 par value |   | CEMI           |   | The NASDAQ Stock Market LLC               |
| Large accelerated filer | ☐ | Accelerated filer         | ☒ |
|-------------------------|---------|---------------------------|---------|
| Non-accelerated filer   | ☐ | Smaller reporting company | ☒ |
|                    |    | Emerging growth company   | ☐ |

----

----

----

|       |                                                                                           | Page |
|------------|------------------------------------------------------------------------------------------------|------|
| PART II    |                                                                                           |
| Item 9B.   | Other Information                                                                              | 5    |
| PART III   |                                                                                           |
| Item 10.   | Directors, Executive Officers and Corporate Governance                                         | 6    |
| Item 11.   | Executive Compensation                                                                         | 14   |
| Item 12.   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 19   |
| Item 13.   | Certain Relationships and Related Transactions, and Director Independence                      | 21   |
| Item 14.   | Principal Accountant Fees and Services                                                         | 22   |
| PART IV    |                                                                                           |
| Item 15.   | Exhibits, Financial Statement Schedules                                                        | 23   |
| Signatures | 24                                                                                             |

----

Table of Contents

----

Table of Contents

| ITEM 9B. | OTHER INFORMATION |
|----------|-------------------|

----

Table of Contents

| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
|----------|--------------------------------------------------------|

| Name                   | Age    | Position(s)                                          |
|------------------------|--------|------------------------------------------------------|
| Non-Employee Directors |   |                                                 |
| Katherine L. Davis     | 63     | Director                                             |
| Mary Lake Polan        | 76     | Director                                             |
| John G. Potthoff       | 52     | Director                                             |
| Executive Officers     |   |                                                 |
| Richard L. Eberly      | 59     | Chief Executive Officer and President                |
| Gail S. Page           | 64     | Executive Chair of the Board                         |
| Neil A. Goldman        | 52     | Executive Vice President and Chief Financial Officer |
| Javan Esfandiari       | 53     | Chief Science and Technology Officer                 |
| Robert Passas          | 66     | Senior Vice President, Chief Commercial Officer      |

| Katherine L. Davis | Director |
|--------------------|----------|

| Mary Lake Polan | Director |
|-----------------|----------|

----

Table of Contents

| John G. Potthoff | Director |
|------------------|----------|

| Richard L. Eberly | Chief Executive Officer and President |
|-------------------|---------------------------------------|

| Gail S. Page | Executive Chair of the Board |
|--------------|------------------------------|

----

Table of Contents

| Neil A. Goldman | Executive Vice President and Chief Financial Officer |
|-----------------|------------------------------------------------------|

| Javan Esfandiari | Executive Vice President and Chief Science and Technology Officer |
|------------------|-------------------------------------------------------------------|

| Robert Passas | Senior Vice President, Chief Commercial Officer |
|---------------|-------------------------------------------------|

----

Table of Contents

|  | • | the audit committee charter at: chembiodiagnosticsinc.gcs-web.com/static-files/9834f839-d259-45c5-8b25-f6fce52b724a; |
|--|---------|----------------------------------------------------------------------------------------------------------------------|
|  | • | the compensation committee charter at: chembiodiagnosticsinc.gcs-web.com/static-files/bd718df4-ee68-4a84-affa-c24f79ceec81; and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | the nominating and corporate governance committee charter at: chembiodiagnosticsinc.gcs-web.com/static-files/264bc05a-d241-4fc8-88d6-9aded84378fb. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | appointing, approving the compensation of, and assessing the independence of our independent auditor; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | approving all audit and non-audit services of the independent auditor; |
|--|---------|------------------------------------------------------------------------|
|  | • | evaluating our independent auditor’s qualifications, performance and independence; |
|--|---------|------------------------------------------------------------------------------------------|
|  | • | reviewing our financial statements and financial disclosure; |
|--|---------|--------------------------------------------------------------|
|  | • | conducting periodic assessments of our accounting practices and policies; |
|--|---------|---------------------------------------------------------------------------|
|  | • | furnishing the audit committee report required by SEC rules; |
|--|---------|--------------------------------------------------------------|
|  | • | reviewing and approving of all related-party transactions; |
|--|---------|------------------------------------------------------------|
|  | • | setting hiring policies for the hiring of employees and former employees or our independent auditor and ensuring that those policies comply with all applicable regulations; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | developing and monitoring compliance with a code of ethics for senior financial officers and a code of conduct for all Chembio employees, officers and directors; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | establishing procedures for the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | overseeing the work of our independent auditor, including resolution of disagreements between management and the independent auditor; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and discussing our annual and quarterly financial statements and related disclosures with management and the independent auditor. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | developing an executive compensation philosophy and establishing and annually reviewing and approving executive compensation programs and policies; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and approving corporate goals and objectives for chief executive officer compensation, evaluating chief executive officer performance based on those goals, and setting chief executive officer compensation; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing chief executive officer recommendations with respect to, and approving annual compensation for, other executive officers; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------|
|  | • | establishing and administering annual and long-term incentive compensation plans for key executives; |
|--|---------|------------------------------------------------------------------------------------------------------|
|  | • | recommending to the board for approval incentive compensation plans and equity-based plans; |
|--|---------|---------------------------------------------------------------------------------------------|
|  | • | reviewing and approving all special executive employment, compensation and retirement arrangements; |
|--|---------|-----------------------------------------------------------------------------------------------------|
|  | • | recommending to the board changes to executive compensation policies and programs; |
|--|---------|------------------------------------------------------------------------------------|
|  | • | recommending to the board all Internal Revenue Service tax-qualified retirement plans; |
|--|---------|----------------------------------------------------------------------------------------|
|  | • | recommending the board all nonqualified benefit plans and periodically reviewing such plans; |
|--|---------|----------------------------------------------------------------------------------------------|
|  | • | reviewing management’s recommendations for other nonexecutive corporate incentive plans; |
|--|---------|------------------------------------------------------------------------------------------------|
|  | • | provide minutes of committee meetings to the board and reporting any significant matters arising from the committee’s work; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------|
|  | • | preparing the report on executive compensation required by SEC rules; |
|--|---------|-----------------------------------------------------------------------|
|  | • | determining procedures for selection of the chief executive officer and other senior management; |
|--|---------|--------------------------------------------------------------------------------------------------|
|  | • | determining procedures for board review of the chief executive officer and other senior management; |
|--|---------|-----------------------------------------------------------------------------------------------------|
|  | • | developing guidelines for, and monitoring compliance with, long-range succession planning; |
|--|---------|--------------------------------------------------------------------------------------------|
|  | • | developing and maintaining, in consultation with the chair of the board and the chief executive officer, a short-term succession plan for unexpected situations affecting the senior management; and |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | monitoring procedures relating to executive development. |
|--|---------|----------------------------------------------------------|
|  | • | reviewing, approving and recommending director candidates to the board of directors; |
|--|---------|--------------------------------------------------------------------------------------|
|  | • | preparing proxy statement disclosure for the process used to identify and evaluate nominees for the board of directors, including an explanation of the director nomination process and shareholder communications to the board; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | periodically reviewing appropriateness of board size and restrictions on board service; |
|--|---------|-----------------------------------------------------------------------------------------|
|  | • | recommending to the board standards regarding our definition of independence as it relates to directors; |
|--|---------|----------------------------------------------------------------------------------------------------------|
|  | • | establishing, coordinating and reviewing with the chair of the board the criteria and method for evaluating the effectiveness of the board; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | developing and recommending to the board procedures for selection of the chair of the board and for board review of and for communications of such review to, the chair of the board; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | monitoring the process and scope of director access to management and employees and communications between directors and management and employees; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | coordinating the board's oversight of our internal control over financial reporting, including disclosure controls; |
|--|---------|---------------------------------------------------------------------------------------------------------------------|
|  | • | developing board meeting procedures; |
|--|---------|--------------------------------------|
|  | • | recommending to the board the number, type, functions, structure and independence of committees; |
|--|---------|--------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | annually recommending to the board membership on board committees and advising board and committees with regard to the selection of chairs of committees; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | determining criteria and procedures for selection of committee members and chairs and establishing and coordinating with the applicable committee chair criteria and method for evaluating the effectiveness of the committees; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | periodically reviewing and revisions of the director orientation program and monitoring, planning and supporting director continuing education activities; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | developing, reviewing and recommending corporate governance policies and monitoring compliance with such policies; and |
|--|---------|------------------------------------------------------------------------------------------------------------------------|
|  | • | providing minutes of committee meetings to the board and reporting significant matters arising from committees’ work. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| ITEM 11. | EXECUTIVE COMPENSATION |
|----------|------------------------|
| Name and Principal Position                                       | Year |   | Salary |    |   | Bonus  |   |    | Stock Awards(1) |   |   | All Other Compensation |   |   | Total  |    |
|-------------------------------------------------------------------|------|--------|--------|---------|--------|--------|--------|---------|-----------------|--------|--------|------------------------|--------|--------|--------|---------|
| John J. Sperzel III(2)                                            | 2019 |   | $      | 463,846 |   |   | $      | — |            |   | $      | 2,175,000              |   |   | $      | — |   |   | $ | 2,638,877 |   |
| Former Chief Executive Officer and President                      | 2018 |   |   | 416,847 |   |   |   | 89,250  |            |   |   | 950,000                |   |   |   | — |   |   |   | 1,456,097 |   |
| Neil A. Goldman                                                   | 2019 |   |   | 319,039 |   |   |   | 23,767  |            |   |   | —                |   |   |   | 4,130   |   |   |   | 347,026 |   |
| Executive Vice President and Chief Financial Officer              | 2018 |   |   | 294,231 |   |   |   | 50,400  |            |   |   | 300,000                |   |   |   | 2,769   |   |   |   | 647,000 |   |
| Javan Esfandiari                                                  | 2019 |   |   | 373,299 |   |   |   | 27,983  |            |   |   | —                |   |   |   | 8,697   |   |   |   | 410,009 |   |
| Executive Vice President and Chief Science and Technology Officer | 2018 |   |   | 357,807 |   |   |   | 72,450  |            |   |   | 375,000                |   |   |   | 7,391   |   |   |   | 791,948 |   |
| (1) | Reflects the aggregate grant date fair value of any restricted common stock granted determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation—Stock                  Compensation. Assumptions used in the calculation of this amount are included in Note 10. Equity Incentive to the Consolidated Financial Statements included in our Annual Report. This amount does not reflect the actual economic                value realized by each named executive officer. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Mr. Sperzel resigned as our Chief Executive Officer and President and one of our directors effective as of January 3, 2020. For additional information, including severance benefits paid to Mr. Sperzel, see “—Employment Agreements” below. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | base salary; |
|--|---------|--------------|
|  | • | performance-based cash bonuses; |
|--|---------|---------------------------------|
|  | • | long-term incentive compensation in the form of restricted stock units and stock options; and |
|--|---------|-----------------------------------------------------------------------------------------------|
|  | • | benefits consisting principally of housing subsidies and health and welfare plan contributions. |
|--|---------|-------------------------------------------------------------------------------------------------|

----

Table of Contents

| Grantee             | Grant Date    | Award Type       | Number of Securities | Equity Compensation Plan    |
|---------------------|---------------|------------------|----------------------|-----------------------------|
| John J. Sperzel III | June 18, 2019 | Restricted stock | 375,000              | 2019 Omnibus Incentive Plan |
|                |   | Option Awards                                                    |    | Stock Awards |                                                                   |
|---------------------|--------|------------------------------------------------------------------|---------|--------------|------------------------------------------------------------------------|
| Name                |   | Number of Securities UnderlyingUnexercised Options(#)Exercisable |    |         | Number of SecuritiesUnderlying Unexercised Options (#)Unexercisable(1) |   |   | OptionExercise Price |   | Option Expiration Date |   | Number of Shares or Units of Stock That Have Not Vested(#)(2) |   |   | Market Value of Shares or Units of Stock That Have Not Vested |   |
| John J. Sperzel III |   |                                                             | 250,000 |         |                                                                   |   | — |   |   | $ | 3.4163 |   | 3/21/21 |   |   | 440,631(3 | ) |   | $ | 2,808,339 |   |
|                |   |                                                             | 5,000   |         |                                                                   |   | — |   |   |   | 5.25 |   | 3/15/22 |   |   | — |   |   |   | — |   |
|                |   |                                                             | — |         |                                                                   |   | 20,000(4 | ) |   |   | 5.3666 |   | 3/31/24 |   |   | — |   |   |   | — |   |
| Neil A. Goldman     |   |                                                             | 83,334  |         |                                                                   |   | 41,667(5 | ) |   |   | 7.04 |   | 12/18/24 |   |   | 20,725(6 | ) |   |   | 199,996 |   |
| Javan Esfandiari    |   |                                                             | 20,000  |         |                                                                   |   | — |   |   |   | 5.64 |   | 3/11/21 |   |   | 25,907(6 | ) |   |   | 250,003 |   |
| (1) | As of December 31, 2019, the aggregate number of unexercisable option awards outstanding was 148,667. |
|-----|-------------------------------------------------------------------------------------------------------|
| (2) | As of December 31, 2019, the aggregate number of unvested stock awards outstanding was 545,986. |
|-----|-------------------------------------------------------------------------------------------------|
| (3) | 375,000 shares of common stock were to vest on November 11, 2022, and one-half of the remaining 65,631 shares of common stock were to vest on each of October 8, 2020 and 2021. All of these unvested shares were forfeited upon Mr.                Sperzel’s termination of employment as of January 3, 2020. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | All of these options were to vest and become exercisable on March 31, 2020. Mr. Sperzel’s right to purchase these unvested shares was cancelled upon the termination of his employment. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | All of these options will vest and become exercisable on December 18, 2020. |
|-----|-----------------------------------------------------------------------------|
| (6) | One-half of these shares will vest and become exercisable on each of October 8, 2020 and 2021. |
|-----|------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | if Mr. Sperzel's employment were to be terminated by reason of “disability” or for “cause,” each as defined in the employment agreement, all compensation, including his base salary, his right to receive a performance bonus, and the                vesting of any unvested equity awards, would cease as of his termination date and he would receive no severance benefits; and |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | we would be required to pay Mr. Sperzel severance benefits that included continued base salary for twelve months, a pro rata annual bonus (based on actual performance), continued payment of our monthly share of health insurance premiums                for twelve months, and accelerated vesting of his outstanding equity awards if: |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | o | Mr. Sperzel's employment were to be terminated by us without “cause” or by Mr. Sperzel for a “reasonable basis” (each as in Sperzel Employment Agreement, which included involuntary termination within a six-month period upon a defined                change of control of Chembio); or |
|--|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | o | we and Mr. Sperzel did not enter into a new employment agreement prior to expiration of the Sperzel Employment Agreement for any reason. |
|--|---|------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Position                                          |   | Annual Cash Retainer |   |
|---------------------------------------------------|--------|----------------------|--------|
| Non-Executive Chair of the Board                  |   | $                    | 65,000 |   |
| All Other Independent Directors                   |   |                 | 30,000 |   |
| Audit Committee Chair                             |   |                 | 12,500 |   |
| Other Audit Committee Members                     |   |                 | 5,000  |   |
| Compensation Committee Chair                      |   |                 | 8,500  |   |
| Other Compensation Committee Members              |   |                 | 3,500  |   |
| Nominating and Governance Committee Chair         |   |                 | 5,000  |   |
| Other Nominating and Governance Committee Members |   |                 | 2,000  |   |
| Director           |   | Fees Earned orPaid in Cash(1) |   |   | Option Awards |   |    | Total  |   |
|--------------------|--------|-------------------------------|--------|--------|---------------|--------|---------|--------|--------|
| Katherine L. Davis |   | $                             | 73,500 |   |          | $      | — |   |   | $ | 73,500 |   |
| Gail S. Page(2)    |   |                          | 43,500 |   |          |   | — |   |   |   | 43,500 |   |
| Mary Lake Polan    |   |                          | 40,500 |   |          |   | — |   |   |   | 40,500 |   |
| John G. Potthoff   |   |                          | 44,500 |   |          |   | — |   |   |   | 44,500 |   |
| (1) | Consist of annual retainer fees, as described in the preceding table. |
|-----|-----------------------------------------------------------------------|
| (2) | Effective January 9, 2020, Ms. Page was appointed as interim Chief Executive Officer, at which time she was no longer considered a non-employee director. Ms. Page served as interim Chief Executive Officer until March 16, 2020 and is                serving as transitional advisor through May 15, 2020. She was appointed to serve as Executive Chair of the Board commencing on April 23, 2020. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
|----------|------------------------------------------------------------------------------------------------|
|  | • | each person known to us to be the beneficial owner of more than five percent of the then-outstanding shares of common stock; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------|
|  | • | each named executive officer included in “Executive Compensation—Summary Compensation Table,” each current director and each nominee for election as a director; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | all of our executive officers, directors and director nominees as a group. |
|--|---------|----------------------------------------------------------------------------|
|                                                                               |   | Common Stock Beneficially Owned |      |
|------------------------------------------------------------------------------------|--------|---------------------------------|-----------|
| Beneficial Owner                                                                   |   | Shares                          |      |   | % |   |
| 5% Stockholders                                                                    |   |                            |      |   |   |   |
| Norman H. Pessin(1)500 Fifth Avenue, Suite 2240New York, NY 10010                  |   |                            | 1,367,587 |   |   |   | 7.8 | % |
| Nantahala Capital Management, LLC(2)130 Main Street, 2nd FloorNew Canaan, CT 06840 |   |                            | 1,239,983 |   |   |   | 7.1 | % |
| Laurence W. Lytton(3)467 Central Park WestNew York, New NY 10025                   |   |                            | 1,010,718 |   |   |   | 5.8 | % |
| Royce & Associates, LP(4)745 Fifth AvenueNew York, NY 10151                    |   |                            | 991,492   |   |   |   | 5.6 | % |
| Named Executive Officers and Directors                                             |   |                            |      |   |   |   |   |   |
| Neil A. Goldman(5)                                                                 |   |                            | 129,236   |   |   |   | * |   |
| Javan Esfandiari(6)                                                                |   |                            | 128,773   |   |   |   | * |   |
| Gail S. Page(7)                                                                    |   |                            | 88,815    |   |   |   | * |   |
| Katherine L. Davis(8)                                                              |   |                            | 90,143    |   |   |   | * |   |
| John G. Potthoff(9)                                                                |   |                            | 65,897    |   |   |   | * |   |
| Mary Lake Polan(10)                                                                |   |                            | 26,522    |   |   |   | * |   |
| John J. Sperzel III(11)91 Hartwell AvenueLexington, MA 02421                       |   |                            | 31,815    |   |   |   | * |   |
| Richard L. Eberly                                                                  |   |                            | 0         |   |   |   | * |   |
| All executive officers and directors as a group (8 persons)(12)                    |   |                            | 586,484   |   |   |   | 3.3 | % |
| * | Less than 1%. |
|---|---------------|
| (1) | Based on an amended Schedule 13D filed on July 18, 2019. |
|-----|----------------------------------------------------------|
| (2) | Based on a Schedule 13G filed on February 14, 2020. As of December 31, 2019, Nantahala may be deemed to be the beneficial owner of 1,239,983 shares held by funds and separately managed accounts under its control, and as the managing                members of Nantahala, each of Messrs. Wilmot B. Harkey and Daniel Mack may be deemed to be a beneficial owner of those shares. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (3) | Based on a Schedule 13G filed on March 20, 2020. Of the shares, 273,264 are held for the benefit of the Lytton-Kambara Foundation, 120,048 shares  for the benefit of the  AWL Family LLC, 21,000 for the benefit of the IKL  Trust, 13,200                for the benefit of the WWL Trust, 9,100 for the benefit of the KLL Trust, and 45,290 shares for the benefit of other accounts of  which the reporting person is deemed to have beneficial ownership. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Based on a Schedule 13G filed on January 21, 2020. |
|-----|----------------------------------------------------|
| (5) | Include (a) 20,725 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 41,666 shares. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Include (a) 25,907 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 20,000 shares. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Include (a) 5,181 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, (b) options to acquire 28,125 shares. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|
| (8) | Include (a) 5,181 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 9,375 shares. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|
| (9) | Include (a) 5,181 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 28,125 shares. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------|
| (10) | Include (a) 5,181 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021 and (b) options to acquire 18,750 shares. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------|
| (11) | Does not include shares of common stock underlying certain options that were received by Mr. Sperzel during his time as our Chief Executive Officer and President and that had              vested as of the time of his resignation. The compensation committee of the board has determined that Mr. Sperzel failed to exercise such options in a timely manner prior to their expiration. Mr. Sperzel has asserted that he continues to have              the right to exercise those options to acquire 266,666 shares for an aggregate exercise price of $943,126. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (12) | Include, in addition to the restricted shares and options described in notes (5) through (10), (a) 6,098 restricted stock units and (b) options to acquire 36,000 shares. Does not include any shares held by Mr. Sperzel. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Plan Category                                          |   | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |    |   | Weighted Average Exercise Price of Outstanding Options, Warrants |   |    | Number of Securities to be Issued Upon Exercise of Outstanding Restricted Stock Units |   |   | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights |   |   | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans |    |
|--------------------------------------------------------|--------|---------------------------------------------------------------------------------------------|---------|--------|------------------------------------------------------------------|--------|---------|---------------------------------------------------------------------------------------|--------|--------|-----------------------------------------------------------------------------|--------|--------|----------------------------------------------------------------------------------------------|---------|
| Equity compensation plans approved by stockholders(1)  |   |                                                                                        | 642,625 |   |                                                             | $      | 5.79    |                                                                                  |   |   | 13,817                                                                      |   |   | $                                                                                            | 9.65    |   |   |   | 2,173,667 |   |
| Equity compensation plans not approved by stockholders |   |                                                                                        | — |   |                                                             |   | — |                                                                                  |   |   | —                                                                     |   |   |                                                                                         | — |   |   |   | — |   |
| Totals                                                 |   |                                                                                        | 642,625 |   |                                                             |   |    |                                                                                  |   |   | 13,817                                                                      |   |   |                                                                                         |    |   |   |   | 2,173,667 |   |
| (1) | “Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights” consists of 99,132 shares under the 2008 Stock Incentive Plan, 336,625 shares under the 2014 Stock Incentive Plan,                and 206,868 shares issued outside of those plans. "Number of Securities to be Issued Upon Exercise of Outstanding Restricted Stock” consists of 13,817 shares under the 2014 Stock Incentive Plan. “Number of Securities Remaining Available for                Future Issuance Under Equity Compensation Plans” consists of 2,173,667 shares available under the 2019 Omnibus Incentive Plan. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. |
|----------|----------------------------------------------------------------------------|

----

Table of Contents

| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
|----------|----------------------------------------|
|                  |   | 2019   |    |   | 2018   |   |
|-----------------------|--------|--------|---------|--------|--------|--------|
| Audit fees(1)         |   | $      | 292,500 |   |   | $      | 548,863 |   |
| Audit-related fees(2) |   |   | 83,500  |   |   |   | 87,780 |   |
| Tax fees(3)           |   |   | 15,375  |   |   |   | 21,000 |   |
| Total Fees            |   | $      | 391,375 |   |   | $      | 657,643 |   |
| (1) | Includes services relating to the audit of annual consolidated financial statements, review of quarterly consolidated financial statements, statutory audits, comfort letters, and consents and review of documentation filed with                SEC-registered and other securities offerings. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Includes services related to assistance with general accounting matters, work performed on acquisitions and divestitures, employee benefit plan audits and assistance with statutory audit matters. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Includes services for tax compliance, tax advice and tax planning. |
|-----|--------------------------------------------------------------------|

----

Table of Contents

| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
|----------|-----------------------------------------|
| (a) | The following is filed as part of the 2019 Form 10-K: |
|-----|-------------------------------------------------------|
|  | (1) | Index to Consolidated Financial Statements in Item 8 of 2019 Form 10-K. |
|--|-----|-------------------------------------------------------------------------|
| (b) | The following exhibits are included herein or incorporated herein by reference. |
|-----|---------------------------------------------------------------------------------|
| Exhibit No.  |   | Description                                                                                                                                                                                                                                                                                                 |
|--------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1          |   | Articles of Incorporation, as amended, of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                         |
| 3.2          |   | Amended and Restated Bylaws, of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                                   |
| 4.1          |   | Warrant to Purchase Common Stock dated as of September 3, 2019, issued by Chembio Diagnostics, Inc. to Perceptive Credit Holdings II, LP                                                                                                                                                                    |
| 10.1(a)*     |   | 2008 Stock Incentive Plan, as amended                                                                                                                                                                                                                                                                       |
| 10.1(b)*     |   | Form of Option for 2008 Stock Incentive Plan                                                                                                                                                                                                                                                                |
| 10.2(a)*     |   | 2014 Stock Incentive Plan                                                                                                                                                                                                                                                                                   |
| 10.2(b)*     |   | Form of Option for 2014 Stock Incentive Plan                                                                                                                                                                                                                                                                |
| 10.3*        |   | 2019 Omnibus Incentive Plan                                                                                                                                                                                                                                                                                 |
| 10.4*        |   | Restated Annual Incentive Bonus Plan of Chembio Diagnostics, Inc., adopted as of March 15, 2019                                                                                                                                                                                                             |
| 10.5*‡ |   | Employment Agreement, dated as of March 4, 2020 and effective as of March 16, 2020, between Chembio                    Diagnostics, Inc. and Richard L. Eberly                                                                                                                                              |
| 10.6*        |   | Letter agreement dated January 17, 2020, between Chembio Diagnostics, Inc. and Gail S. Page                                                                                                                                                                                                                 |
| 10.7(a)*     |   | Employment Agreement dated March 5, 2016 between Chembio Diagnostics, Inc. and Javan Esfandiari                                                                                                                                                                                                             |
| 10.7(b)*     |   | Amendment No. 1 dated March 20, 2019 between Chembio Diagnostics, Inc. and Javan Esfandiari, amending the Employment Agreement dated March 5, 2016                                                                                                                                                          |
| 10.8*        |   | Employment Agreement dated September 14, 2017 between Chembio Diagnostics, Inc. and Sharon Klugewicz                                                                                                                                                                                                        |
| 10.9(a)*     |   | Employment Agreement dated December 18, 2017 between Chembio Diagnostics, Inc. and Neil A. Goldman                                                                                                                                                                                                          |
| 10.9(b)*     |   | Amendment No. 1 dated January 21, 2019 between Chembio Diagnostics, Inc. and Neil A. Goldman, amending Employment Agreement dated December 18, 2017                                                                                                                                                         |
| 10.10*       |   | Offer Letter dated October 19, 2016 between Worldwide Workplace Ireland and Robert Passas, with respect to employment by Chembio Diagnostics                  Systems, Inc.                                                                                                                                 |
| 10.11        |   | Separation and Release Agreement, dated January 7, 2020, between Chembio Diagnostics, Inc. and John J. Sperzel III                                                                                                                                                                                          |
| 10.12(a)     |   | Lease Agreement, dated February 15, 2017, between Horseblock Associates and Chembio Diagnostics, Inc. with respect to 3661 Horseblock Road,                  Medford, New York, as amended                                                                                                                  |
| 10.12(b)     |   | Agreement of Sublease dated February 5, 2019 between Chembio Diagnostic Systems Inc., as sublessor, and Reliance Communications of New Jersey, LLC, as                  sublessee, with respect to 3661 Horseblock Road, Medford, New York, as amended                                                      |
| 10.13        |   | Lease Agreement, dated February 4, 2013, between Sherwood Corporate Center LLC and Chembio Diagnostics, Inc. with respect to 91-1A Colin                  Drive, Holbrook, New York, as amended on September 19, 2017                                                                                       |
| 10.14        |   | Lease Agreement dated February 5, 2019 between Myra Properties, LLC, as lessor, and Chembio Diagnostic Systems Inc., as lessee, with respect to 555                  Wireless Boulevard, Hauppauge, New York.                                                                                               |
| 10.15† |   | Credit Agreement and Guaranty dated as of September 3, 2019, among Chembio Diagnostics, Inc., as the Borrower, the Guarantors from time to time party                  thereto, and Perceptive Credit Holdings II, LP and its successors and assigns party thereto, as Administrative Agent and as a Lender |
| 14.1         |   | Ethics Policy                                                                                                                                                                                                                                                                                               |
| 21.1         |   | List of Subsidiaries of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                                           |
| 23.1         |   | Consent of BDO USA, LLP, Independent Registered Public Accounting Firm                                                                                                                                                                                                                                      |
| 31.1         |   | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                     |
| 31.2         |   | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                     |
| 32.1ç   |   | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the                  Sarbanes-Oxley Act of 2002                                                                                                               |
| 101.INS      |   | XBRL Instance Document                                                                                                                                                                                                                                                                                      |
| 101.SCH      |   | XBRL Taxonomy Extension Schema Document                                                                                                                                                                                                                                                                     |
| 101.CAL      |   | XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                                                                                                                                       |
| 101.DEF      |   | XBRL Taxonomy Definition Linkbase Document                                                                                                                                                                                                                                                                  |
| 101.LAB      |   | XBRL Taxonomy Label Linkbase Document                                                                                                                                                                                                                                                                       |
| 101.PRE      |   | XBRL Taxonomy Presentation Linkbase Document                                                                                                                                                                                                                                                                |
| * | Indicates management contract or compensatory plan. |
|---|-----------------------------------------------------|
| † | Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of omitted exhibits and schedules upon request by the Securities and Exchange Commission,                provided that it may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for exhibits and schedules so furnished. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ‡ | Certain sensitive personally identifiable information in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ç | The certifications attached as Exhibit 32.1 accompany the Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the                registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                        | CHEMBIO DIAGNOSTICS, INC. |
|-----------------------------|---------------------------|
|                        |                      |   |
| Dated:  April 29, 2020 | By:                       | /s/ Neil A. Goldman |
|                        |                      | Name: Neil A. Goldman |
|                        |                      | Title: Executive Vice President and Chief Financial Officer |

----